RotaTeq® and Meningococcus C Vaccine in Healthy Infants (V260-016)

PHASE3CompletedINTERVENTIONAL

Enrollment

247

Participants

Timeline

Start Date

February 13, 2007

Primary Completion Date

September 4, 2007

Study Completion Date

October 23, 2007

Conditions

Meningitis, MeningococcalRotavirus Infections

Interventions

BIOLOGICAL

RotaTeq®

Rotavirus vaccine, live, oral, pentavalent, 2 mL solution for oral administration.

BIOLOGICAL

NeisVac-C®

Meningiococcal Group C Polysaccharide Conjugate Vaccine Absorbed, 0.5 mL suspension for intramuscular injection.

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00443846 - RotaTeq® and Meningococcus C Vaccine in Healthy Infants (V260-016) | Biotech Hunter | Biotech Hunter